<DOC>
	<DOCNO>NCT00634595</DOCNO>
	<brief_summary>Angiogenesis , formation new blood vessel exist vessel , essential tumor growth metastasis . Antiangiogenic therapy inhibit growth genetically stable endothelial cell , tumor starve death little acquire resistance . Endostatin show block endothelial cell proliferation , survival , migration . Antitumor activity endostatin protein demonstrate various murine human tumor animal model study without detectable toxicity . Endostatin gene therapy could directly express highly bioactive protein vivo mean mechanism eukaryotic expression system post-translational modification folding , well overcome challenge long-term storage cumbersome daily administration endostatin protein . E10A replication-deficient recombinant adenovirus contain wild-type human endostatin transgene construct serotype 5 adenovirus ( Ad5 ) . Preclinical study demonstrate intratumoral injection E10A provide significant tumor growth inhibition sustain elevation endostatin blood tumor tissue hepatocellular carcinoma , nasopharyngeal carcinoma , tongue cancer animal model . A Phase I clinical trial E10A conduct show repetitive intratumoral injection E10A result small sustained elevation endostatin blood mild antitumor activity limit toxicity . The major toxicity transient manageable fever . A randomized Phase III trial nonsmall-cell lung cancer show endostatin improve response rate time tumor progression combination chemotherapy . Therefore , design randomized phase II trial explore safety effectiveness E10A combine chemotherapy treatment patient head neck cancer .</brief_summary>
	<brief_title>Trial E10A Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>histologically cytologically confirm recurrent metastatic head neck squamous carcinoma nasopharyngeal carcinoma tumor amenable direct injection measurement ( &gt; 2 cm ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 life expectancy three month absence serious medical psychiatric disorder serum creatinine &lt; 1.5 mg/dL ; WBC count &gt; 3,000/mm3 , platelet count &gt; 80,000/mm3 , hemoglobin &gt; 8 g/dL ; total bilirubin value &lt; 1.5 time upper limit normal [ ULN ] , ALT level &lt; 2.5 time ULN , AST &lt; 2.5 time ULN . pregnant breast feed history brain metastasis primary brain tumor history hemorrhagic diathesis history corticosteroid immunosuppressive use within four week study entry history immune deficiency disorder organ transplant evidence active adenovirus infection uncontrolled infection receive chemotherapy radiotherapy within four week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>clinical trial</keyword>
	<keyword>randomize</keyword>
	<keyword>Endostatin</keyword>
	<keyword>gene therapy</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>head neck squamous carcinoma</keyword>
</DOC>